| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Common Stock |
7.69M |
$146M |
$19.00 |
Jun 28, 2021 |
Indirect |
| Savara Inc |
10%+ Owner |
Common Stock |
24.5M |
$109M |
$4.45 |
Jul 17, 2023 |
Indirect |
| Korro Bio, Inc. |
10%+ Owner |
Common Stock |
1.09M |
$61.1M |
$56.00 |
Apr 22, 2024 |
Indirect |
| MBX Biosciences, Inc. |
10%+ Owner |
Common Stock |
3.61M |
$38.6M |
$10.69 |
Sep 16, 2024 |
Indirect |
| Trevi Therapeutics, Inc. |
10%+ Owner |
Common Stock |
10.4M |
$21.1M |
$2.02 |
Apr 11, 2022 |
Indirect |
| ARDELYX, INC. |
10%+ Owner |
Common Stock |
2.26M |
$15M |
$6.64 |
Dec 15, 2021 |
Indirect |
| Coursera, Inc. |
10%+ Owner |
Common Stock |
100K |
$1.85M |
$18.39 |
Feb 15, 2023 |
Indirect |
| Metacrine, Inc. |
10%+ Owner |
Common Stock |
2.56M |
$1.2M |
$0.47 |
Dec 22, 2021 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Class A Common Stock |
36.7K |
$451K |
$12.28 |
May 2, 2022 |
Indirect |
| IonQ, Inc. |
10%+ Owner |
Common Stock |
9.53K |
$126K |
$13.21 |
Nov 16, 2022 |
Indirect |
| AVEO PHARMACEUTICALS, INC. |
10%+ Owner |
Common Stock |
3.22K |
$48.3K |
$15.00 |
Oct 19, 2022 |
Indirect |
| Sagimet Biosciences Inc. |
10%+ Owner |
Series A Common Stock |
11.3K |
$46.3K |
$4.10 |
Jan 29, 2024 |
Indirect |
| Mirum Pharmaceuticals, Inc. |
10%+ Owner |
Common Stock |
1.55K |
$43.4K |
$28.04 |
Jun 13, 2023 |
Indirect |
| Desktop Metal, Inc. |
10%+ Owner |
Class A Common Stock |
7.33K |
$5.38K |
$0.73 |
Jun 8, 2021 |
Indirect |
| Eargo, Inc. |
10%+ Owner |
Common Stock |
1.63K |
$4.22K |
$2.59 |
May 24, 2021 |
Indirect |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Common Stock |
0 |
$0 |
$6.84 |
Oct 2, 2025 |
Indirect |
| Trevi Therapeutics, Inc. |
10%+ Owner |
3.5-Year Common Stock Warrant |
1.85M |
|
|
Oct 18, 2021 |
Indirect |
| Trevi Therapeutics, Inc. |
10%+ Owner |
7-Year Common Stock Warrant |
1.85M |
|
|
Oct 18, 2021 |
Indirect |
| Akouos, Inc. |
10%+ Owner |
Common Stock |
0 |
|
$12.50 |
Nov 30, 2022 |
Indirect |
| Arcellx, Inc. |
10%+ Owner |
Common Stock |
0 |
|
$55.27 |
Dec 22, 2022 |
Indirect |
| GENOCEA BIOSCIENCES, INC. |
10%+ Owner |
Common Stock |
0 |
|
$1.25 |
May 25, 2022 |
Indirect |
| MBX Biosciences, Inc. |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
Indirect |
| MBX Biosciences, Inc. |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Sep 16, 2024 |
Indirect |
| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series A-2 convertible preferred stock |
0 |
|
|
Jun 28, 2021 |
Indirect |
| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
Jun 28, 2021 |
Indirect |
| Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series C convertible preferred Stock |
0 |
|
$2.96 |
Jun 28, 2021 |
Indirect |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Series A Convertible Perpetual Preferred Stock |
0 |
|
|
Oct 2, 2025 |
Indirect |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Series B Convertible Perpetual Preferred Stock |
0 |
|
|
Oct 2, 2025 |
Indirect |
| NeueHealth, Inc. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Oct 2, 2025 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Common Stock |
0 |
|
$34.32 |
Aug 2, 2021 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Series B Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 2, 2021 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 2, 2021 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Series D Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 2, 2021 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Series E Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 2, 2021 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Series F Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 2, 2021 |
Indirect |
| Robinhood Markets, Inc. |
Director |
Tranche I Convertible Promissory Note |
0 |
|
|
Aug 2, 2021 |
Indirect |